Status:
RECRUITING
Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Lead Sponsor:
Federico II University
Conditions:
Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Molecular analysis identifies residual disease by overcoming the sensitivity of imaging methods and therefore has the potential for integrating with therapy provided by FDG-PET alone. It is a well kno...
Detailed Description
A clinical need, not yet met for the Hodgkin lymphoma disease, brings about the early and accurate identification of chemo-refractory patients who require stepping up of treatment as also, patients wi...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male or female adults 18 years or older
- Documented diagnosis of Hodgkin lymphoma (both classic and nodular predominant lymphocytes subtype) according to 2016 WHO classification
- Willing and able to comply with scheduled study procedures
- Evidence of a signed informed consent
- ECOG performance status 0-2 (or 3, if disease related)
Exclusion
Key Trial Info
Start Date :
January 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 3 2026
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT05254821
Start Date
January 10 2022
End Date
February 3 2026
Last Update
November 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federico II University
Naples, Italy, 80130